Jan Basile to Cardiovascular Diseases
This is a "connection" page, showing publications Jan Basile has written about Cardiovascular Diseases.
Connection Strength
2.724
-
A Multifactorial Approach to Reduce Cardiovascular Disease in Type 2 Diabetes Mellitus: Now More Than Ever. Hosp Pract (1995). 2016; 44(1):9-20.
Score: 0.303
-
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013 May-Jun; 27(3):280-6.
Score: 0.246
-
Review of recent literature: Existing kidney disease classification guideline needs to incorporate degree of proteinuria with estimated glomerular filtration rate to more accurately predict cardiovascular and renal risk. J Clin Hypertens (Greenwich). 2010 Aug; 12(8):627-30.
Score: 0.207
-
Largest meta-analysis to date suggests that patients at risk for cardiovascular disease events derive benefit from antihypertensive therapy regardless of baseline blood pressure and to reduce vascular events, lowering blood pressure is more important than choice of antihypertensive drug class. J Clin Hypertens (Greenwich). 2009 Dec; 11(12):743-5.
Score: 0.198
-
Lessons learned from the ONTARGET and TRANSCEND trials. Curr Atheroscler Rep. 2009 Sep; 11(5):371-6.
Score: 0.194
-
Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Int J Clin Pract. 2009 Apr; 63(4):656-66.
Score: 0.187
-
Recognizing the link between CKD and CVD in the primary care setting: accurate and early diagnosis for timely and appropriate intervention. South Med J. 2007 May; 100(5):499-505.
Score: 0.165
-
Management of global risk across the continuum of hypertensive heart disease. J Clin Hypertens (Greenwich). 2006 Aug; 8(8 Suppl 2):21-30; quiz 39-40.
Score: 0.157
-
Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. J Cardiometab Syndr. 2006; 1(5):358-61.
Score: 0.151
-
Analysis of recent papers in hypertension. J Clin Hypertens (Greenwich). 2004 Feb; 6(2):96-101.
Score: 0.132
-
A statewide primary care approach to cardiovascular risk factor control in high-risk diabetic and nondiabetic patients with hypertension. J Clin Hypertens (Greenwich). 2004 Jan; 6(1):18-25.
Score: 0.131
-
Beta-blockers for treatment of hypertension. Postgrad Med. 2003 Dec; 114(6 Suppl Role):11-7.
Score: 0.130
-
Orthostatic Hypotension in the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Blood Pressure Trial: Prevalence, Incidence, and Prognostic Significance. Hypertension. 2016 10; 68(4):888-95.
Score: 0.079
-
Recent clinical trials. J Am Soc Hypertens. 2014 Oct; 8(10):770-4; quiz 775-6.
Score: 0.069
-
Analysis of recent papers in hypertension. Initial combination therapy provides more prompt blood pressure control and reduces cardiovascular events but remains underutilized. J Clin Hypertens (Greenwich). 2013 Aug; 15(8):523-5.
Score: 0.063
-
Is there accord in ACCORD? Lower blood pressure targets in type 2 diabetes does not lead to fewer cardiovascular events except for reductions in stroke. J Clin Hypertens (Greenwich). 2010 Jul 01; 12(7):472-7.
Score: 0.051
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29; 362(17):1575-85.
Score: 0.050
-
Identifying and managing factors that interfere with or worsen blood pressure control. Postgrad Med. 2010 Mar; 122(2):35-48.
Score: 0.050
-
Does prehypertension represent an increased risk for incident hypertension and adverse cardiovascular outcome? Hypertension. 2009 Nov; 54(5):954-5.
Score: 0.049
-
Cardioprotection: the role of beta-blocker therapy. J Clin Hypertens (Greenwich). 2005 Jul; 7(7):409-16.
Score: 0.036
-
Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich). 2004 Mar; 6(3):116-25.
Score: 0.033
-
Systolic blood pressure elevation: it's where the action is. Drugs Aging. 2003; 20(4):287-8.
Score: 0.031
-
Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006 Sep; 48(3):374-84.
Score: 0.010